Sorrento Therapeutics Inc. (SRNE) News
Filter SRNE News Items
SRNE News Results
|Loading, please wait...|
SRNE News Highlights
- SRNE's 30 day story count now stands at 8.
- Over the past 23 days, the trend for SRNE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BA, BEAT and CE are the most mentioned tickers in articles about SRNE.
Latest SRNE News From Around the Web
Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses
STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses, including Omicron BA.1 (+R346K mutation).An IND application for COVISHIELD™ IN, formulated for intranasal (IN) administration for clinical use in the context of early symptomatic and asymptomatic infections, was submitted to the FDA on February 1, 2022. SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) --
Sorrento Therapeutics (NASDAQ:SRNE) announced the acquisition of Chinese-based diagnostic test maker, Zhengzhou Fortune Bioscience as the company plans to ramp up the production of its COVISTIX COVID-19 VIRUS Rapid Antigen Detection Test. The deal includes an option for Sorrento (SRNE) to acquire 100% of the company. The financial terms of...
Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™
COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant.COVISTIX has an enhanced sensitivity in detecting the Omicron variant with a more than 10-fold lower limit of detection (LoD) as compared to that of the original SAR-CoV-2 strain.COVISTIX has been approved for emergency use and is on the market in Brazil and Mexico, and is CE marked for sale in Europe for professional point-of-care use.In response
Analysts Estimate Sorrento Therapeutics (SRNE) to Report a Decline in Earnings: What to Look Out for
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech stocks are going through a historic drawdown at the moment. Nearly 400 publicly traded biotech companies have lost 40% or more of their value in just the past six months. Many of these beaten-down biotech stocks will ultimately rebound.
Sorrento Therapeutics Chairman and CEO Henry Ji joins Yahoo Finance Live to discuss the Covishield antibody Sorrento is developing, the timeline for getting FDA approval, cancer treatment research, and the pharmaceutical biotech sectors.
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable at-home diagnostic platform (“Virex Technology”).Virex Technology, invented and developed by Boston University (BU) Professors Mark Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry found in household diabetes glucometer devices for next generation diagnostics.Virex Technology has demonstrated extremely high sensitivity for multiple biological analytes inclu
Sorrento Therapeutics Inc''s (NASDAQ: SRNE ) late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits omicron virus entry and replication in cell-based assays . In VeroE6 cells challenged with omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity Full story available on Benzinga.com
Sorrento Therapeutics (SRNE) said its preclinical candidate STI-1558 effectively inhibits Omicron virus entry and replication in cell-based assays.The company said that in